Richard Schilsky, M.D.

Dr. Richard L. Schilsky is a renowned oncologist and clinical pharmacologist with a career spanning over four decades. He is recognized for his expertise in gastrointestinal cancers, cancer pharmacology, and precision medicine. Dr. Schilsky served as the Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO) from 2013 to 2021. Prior to that, he spent nearly 30 years at the University of Chicago, where he held leadership roles, including Director of the Comprehensive Cancer Center, Associate Dean for Clinical Research and Chief of Hematology/Oncology.

From 1995 to 2010, Dr. Schilsky served as chair of the Cancer and Leukemia Group B, a national cooperative cancer research group funded by the National Cancer Institute (NCI), now part of the Alliance for Clinical Trials in Oncology. He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA. Presently, he serves as chair of the Board of the Reagan-Udall Foundation for the FDA, and as a member of the Board of Directors of Friends of Cancer Research. Dr. Schilsky has served on the editorial boards of many cancer journals, including the Journal of Clinical Oncology. He presently serves on the editorial board of the New England Journal of Medicine. Dr. Schilsky is the author of more than 450 original research articles, reviews and commentaries.